Right Ventricular Outflow Tract Arrhythmias: Benign Or Early Stage Arrhythmogenic Right Ventricular Cardiomyopathy/ Dysplasia?

GSergio Conti, MD1, Laura Cipolletta, MD1, Vittoria Marino, MD1, Martina Zucchetti, MD1, Eleonora Russo, MD1, Francesca Pizzamiglio, MD1, Ghaliah Al-Mohani, MD1, Salvatore Pala, BE1, Valentina Catto, BE, PhD1, Luigi Di Biase, MD, PhD2,3,4,5, Andrea Natale, MD2,6,7,8, Claudio Tondo, MD, PhD, FESC1, Corrado Carbucicchio, MD1

1Cardiac Arrhythmia Research Centre, Centro Cardiologico Monzino IRCCS, Milan, Italy. 2Texas Cardiac Arrhythmia Institute at St David’s Medical Centre, Austin, TX, USA. 3Albert Einstein College of Medicine at Montefiore Hospital, New York, USA. 4Cardiology Department, University of Foggia, Foggia, Italy. 5Department of Biomedical Engineering, University of Texas, Austin, USA. 6Division of Cardiology, Stanford University, CA, USA. 7Case Western Reserve University, Cleveland, OH, USA. 8EP Services, California Pacific Medical Center, San Francisco, CA, USA. 9Interventional Electrophysiology, Scripps Clinic, San Diego, CA, USA.

Abstract

Ventricular arrhythmias (VAs) arising from the right ventricular outflow tract (RVOT) are a common and heterogeneous entity. Idiopathic right ventricular arrhythmias (IdioVAs) are generally benign, with excellent ablation outcomes and long-term arrhythmia-free survival, and must be distinguished from other conditions associated with VAs arising from the right ventricle: the differential diagnosis with arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is therefore crucial because VAs are one of the most important causes of sudden cardiac death (SCD) in young individuals even with early stage of the disease. Radiofrequency catheter ablation (RFCA) is a current option for the treatment of VAs but important differences must be considered in terms of indication, purposes and procedural strategies in the treatment of the two conditions. In this review, we comprehensively discuss clinical and electrophysiological features, diagnostic and therapeutic techniques in a compared analysis of these two entities.

Introduction

The right ventricular outflow tract (RVOT) is the most common origin of non-ischemic ventricular arrhythmias (VAs). RVOT VAs - including premature ventricular contractions (PVCs) and non-sustained or sustained ventricular tachycardia (VT) - are the expression of two different entities, both in terms of natural history and in terms of therapeutic management: idiopathic right ventricular arrhythmias (IdioVAs) and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).1,2

Key Words:

IdioVAs is a benign condition that occurs in young adults without structural heart disease, traditionally considered a primary electrical disease, responsive to medical and ablative therapy.3,4 ARVC/D is an autosomal dominant genetically determined heart muscle disorder characterized by pathological fibro-fatty replacement of the right ventricular (RV) myocardium, that leads to VAs, RV dysfunction and sudden cardiac death (SCD).5-7 In the early stage of the disease, structural changes may be absent or subtle, progressively affecting localized areas of the RV, typically the inflow tract, outflow tract, or apex of the RV, the so-called “triangle of dysplasia”.8 However, the subsequent involvement of other regions of the RV is common.9 Whilst in the past the involvement of the left ventricle (LV) was considered an expression of the final stage of the disease, known as “biventricular failure phase”, it is currently recognized that ARVC/D can present with isolated or predominant involvement of LV since the early stages.10 Clinical and genetic characterization of families demonstrated 3 different patterns of ARVC/D: classic pattern with predominant RV disease; left dominant pattern, with early and prominent LV disease; bi-ventricular pattern, with synchronous involvement of both ventricles.11 The diagnosis of ARVC/D relies on the demonstration of structural, functional, and electrophysiological abnormalities, as defined by the 2010 modified Task Force criteria.
Radiofrequency catheter ablation (RFCA) is a highly effective treatment for symptomatic patients with IdioVAs, whilst the role of ablation in ARVC/D is not definitively curative. As such, differentiating between the two conditions is essential because different procedural endpoints should be defined and different ablation strategies are required.

The revised Task Force criteria of 2010 for the diagnosis of ARVC/D are as follows:

### Table 1: Revised Task Force (TF) criteria of 2010.12

<table>
<thead>
<tr>
<th>Major Criteria</th>
<th>Minor Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Global or regional dysfunction and structural alterations</strong></td>
<td><strong>Regional RV akinesia, dyskinesia, or aneurysm and 1 of the following (end diastole):</strong></td>
</tr>
<tr>
<td><strong>2D echo</strong></td>
<td>PLAX RVOT ≥32 mm (corrected [PLAX/BSA] ≥19 mm/m²)</td>
</tr>
<tr>
<td></td>
<td>PSAX RVOT ≥36 mm (corrected [PSAX/BSA] ≥21 mm/m²)</td>
</tr>
<tr>
<td></td>
<td>or fractional area change ≥33%</td>
</tr>
<tr>
<td><strong>MRI</strong></td>
<td>Regional RV akinesia or dyskinesia or dysynchronous RV contraction and 1 of the following:</td>
</tr>
<tr>
<td></td>
<td>Ratio of RVEDV to BSA ≥110 mL/m² (male) or ≥100 mL/m² (female)</td>
</tr>
<tr>
<td></td>
<td>or RV ejection fraction ≤40%</td>
</tr>
<tr>
<td><strong>RV angiography</strong></td>
<td>Regional RV akinesia, dyskinesia, or aneurysm</td>
</tr>
<tr>
<td><strong>2D echo</strong></td>
<td>Regional RV akinesia or dyskinesia and 1 of the following (end diastole):</td>
</tr>
<tr>
<td></td>
<td>PLAX RVOT ≥32 mm (corrected [PLAX/BSA] ≥19 mm/m²)</td>
</tr>
<tr>
<td></td>
<td>PSAX RVOT ≥36 mm (corrected [PSAX/BSA] ≥21 mm/m²)</td>
</tr>
<tr>
<td></td>
<td>or fractional area change ≥33%</td>
</tr>
<tr>
<td><strong>MRI</strong></td>
<td>Regional RV akinesia or dyskinesia or dysynchronous RV contraction and 1 of the following:</td>
</tr>
<tr>
<td></td>
<td>Ratio of RVEDV to BSA ≥110 mL/m² (male) or ≥100 mL/m² (female)</td>
</tr>
<tr>
<td></td>
<td>or RV ejection fraction &gt; 40% ≤45%</td>
</tr>
<tr>
<td><strong>Tissue characterization of wall</strong></td>
<td>Residual myocytes &lt;60% by morphometric analysis (or &lt;50% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on EMB</td>
</tr>
<tr>
<td><strong>Minor Criteria</strong></td>
<td>Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on EMB</td>
</tr>
<tr>
<td><strong>Depolarization/conduction abnormalities</strong></td>
<td>Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V1 to V3)</td>
</tr>
<tr>
<td><strong>Major Criteria</strong></td>
<td>Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V1 to V3)</td>
</tr>
<tr>
<td><strong>Minor Criteria</strong></td>
<td>Late potentials by SAECG in ≥1 of 3 parameters in the absence of a QRS duration of ≥110 ms on the standard ECG</td>
</tr>
<tr>
<td><strong>Arrhythmias</strong></td>
<td>Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V1 to V3)</td>
</tr>
<tr>
<td><strong>Major Criteria</strong></td>
<td>Filtered QRS duration (fQRS) ≥114 ms</td>
</tr>
<tr>
<td><strong>Minor Criteria</strong></td>
<td>Duration of terminal QRS &lt;40 μV (low-amplitude signal duration) ≤38 ms</td>
</tr>
<tr>
<td><strong>Family History</strong></td>
<td>Terminal activation duration of QRS ≥55 ms measured from the nadir of the S wave to the end of the QRS, including R’, in V1, V2, or V3, in the absence of complete RBBB</td>
</tr>
<tr>
<td><strong>Major Criteria</strong></td>
<td>ARVC/D confirmed in a first-degree relative who meets current TF criteria</td>
</tr>
<tr>
<td><strong>Minor Criteria</strong></td>
<td>ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative</td>
</tr>
</tbody>
</table>

RV = right ventricle, PLAX = parasternal long-axis, RVOT = right ventricular outflow tract, BSA = body surface area, PSAX = parasternal short axis, RVEDV = right ventricular end-diastolic volume, EMB = endomyocardial biopsy, RBBB = right bundle-branch block, SAECG = signal-averaged ECG, LBBB = left bundle-branch block, SCD = sudden cardiac death.
Clinical Presentation And ECG Of Ventricular Arrhythmias In Patients With IdioVAs And ARVC/D

Clinical presentation of IdioVAs typically includes palpitations, dizziness, related to frequent PVCs or non-sustained VT. Less frequently, physical exercise or emotional stress can lead to sustained VT that may be occasionally the cause for syncope. On the other hand, clinical presentation of ARVC/D may be variable: palpitations, but also syncope, cardiac arrest or SCD have been reported. Traditionally, 3 different phases have been distinguished. In the early “concealed phase”, patients are commonly asymptomatic, with minor VAs and subtle RV structural changes. However, risk of SCD is reported particularly during exercise. In the second phase, “overt electrical phase”, patients present symptomatic VAs and morphological RV abnormalities detected by imaging. Finally, the third phase is the “end-stage-disease”, often indistinguishable from dilated cardiomyopathy.

Several ECG markers related to ARVC/D have been described. According to the Revised Task Force criteria, summarized in Table 1, evidence of negative precordial T-wave in V1-V3 or beyond and epsilon wave in V1-V3 on sinus rhythm are major criteria. Regarding presentation with VAs, the typical inferior axis / left bundle branch block (LBBB) pattern is common in more than 90% of IdioVAs patients. Differently, ARVC/D patients present with inferior axis as well as intermediate axis or superior axis VAs. Recently, Hoffmayer et al. compared ARVC/D and IdioVAs patients in a population presenting with the same inferior axis / LBBB ECG morphology, finding several distinguishing criteria between the two conditions. With regard to the diagnosis of ARVD/C, QRS duration ≥ 120 ms in lead I was highly sensitive (88%), whereas a “notching” on QRS upstroke (88%), multiple QRS notching in different leads (88%), earliest QRS onset in V1 (90%), late (V5; 90%) and very late (V6; 100%) precordial transition were all highly specific criteria. For clinical purposes, ECG characteristics of different sites of RVOT and the left ventricular outflow tract (LVOT) VAs are given in Table 2.

In the Revised Task Force criteria, Signal Averaged Electrocardiography (SAECG) is a minor criterion of ARVC/D. However, O’Donnell and coworkers found that late potentials (LPs) on the SAECG were not present in any patient with RVOT tachycardia but were present in 78% of the patients with ARVC/D. Moreover, in a recent non-invasive ECG study, the SAECG parameters and the frequency components recorded from the wavelet-transformed ECG were compared between three different groups: IdioVAs, ARVC/D and Brugada syndrome. Focusing on the first two entities, LPs were positive in all of ARVC/D patients whilst were negative in all of IdioVAs patients and high-frequency components (80-150 Hz) were developed in ARVC/D but not in IdioVAs. Electrophysiological Differences Between IdioVAs And Ventricular Arrhythmias In ARVC/D

Taking into account the different underlying substrate of the two entities, electrophysiological findings help to differentiate IdioVAs from VAs in the setting of ARVC/D. Different groups compared electrophysiological findings in patients with IdioVAs and ARVC/D reporting similar results. IdioVAs are due to cyclic AMP mediated triggered activity. Thus, it is a focal form of tachycardia, frequently presenting in form of non-sustained arrhythmias, sensitive to catecholamine infusion (i.e. epinephrine, phenylephrine or isoproterenol) and burst stimulation; for the same reason IdioVAs are monomorphic with the common inferior axis – LBBB morphology and present a presystolic high amplitude local electrogram.

VAs in context of ARVC/D are the expression of slow conduction areas within the diseased myocardium that allow continuous electrical activity, fragmented diastolic potentials (figure 2) in an expanded area, creating a circuit pathway. For this reason, programmed ventricular stimulation is more effective to induce VT in ARVC/D patients compared with IdioVAs. Moreover, the evidence of different reentry pathways justifies the inducibility of multiple VT morphologies that may be common in ARVC/D patients.

Imaging - Cardiac Magnetic Resonance

Cardiac magnetic resonance (CMR) imaging is increasingly used as a standard technique for imaging of RV structure and function. Indeed, CMR is the most reliable modality available for the quantification of ventricular size and volume and for the detection of RV morphological abnormalities due to its capacity to perform tissue characterization.
Although IdioVAs occur in patients with no structural heart disease, several groups reported that CMR imaging detected structural abnormalities in patients with IdioVAs, which are similar to those seen in the early stages of ARVC/D. CMR showed subtle areas of diminished wall motion and suggested that mild structural abnormalities may be present. These findings made the differentiation of ARVC/D and RVOT tachycardia at the time of initial diagnosis more difficult in some patients. In clinical routine CMR imaging is of fundamental value in the diagnosis of ARVC/D; however, a suspicion of ARVC/D cannot be confirmed or excluded based on CMR imaging alone.

On the other hand, it is well established that the typical morphological features of ARVC/D are RV dilatation and/or dysfunction, wall motion abnormalities, diastolic bulging, wall thinning, reduced systolic thickening and trabecular disarray. Moreover, CMR has the unique ability to detect diffuse or segmental replacement of myocardium in the RV free wall by fibro-fatty tissue. Delayed enhancement (DE) CMR is effective in detecting the presence, location, and extent of myocardial scarring. DE has been described in areas of fibro-fatty myocardial changes in patients with ARVC/D. Tandri et al. first reported an excellent correlation between DE and histopathological diagnosis of fibro-fatty infiltration in patients with ARVC/D. Moreover, they showed that the presence of RV DE was predictive of inducible VT during electrophysiological study. Another group reported DE in 88% of patients studied with ARVC/D; DE predominantly involved the RV free wall but also affected the RV side of the ventricular septum and, in most of the patients, it was associated with regional contraction abnormality. A significant inter-observer variability in the interpretation of qualitative findings and segmental contraction analysis of the RV free wall was reported: CMR was implicated in the overdiagnosis of ARVC/D based on the low specificity of qualitative findings, such as increased intramyocardial fat and wall thinning. A CMR study demonstrated a 93.1% prevalence of RV wall motion abnormalities in healthy subjects, including areas of apparent dyskinesia (75.9%) and bulging (27.6%). These data indicate that conventional CMR may lead to misdiagnosis of ARVC/D by showing equivocal morphofunctional RV abnormalities. Noteworthily, even if CMR is considered an important test for ARVC/D diagnosis may not detect the initial phases of the disease.

### The Adjunctive Role Of Three-Dimensional Electroanatomical Voltage Mapping

Three-dimensional electroanatomical voltage mapping (3D-EAVM) using CARTO system (Biosense-Webster, Diamond Bar, CA, USA) is able to unmask subtle structural heart disease in patients with VAs and an apparently normal heart, despite a thorough noninvasive evaluation, including CMR. Specifically, 3D-EAVM accurately identifies and characterizes low-voltage regions (“electroanatomical scar”) that, in patients with ARVC/D, correspond to areas of myocardial depletion and correlate with
in ARVC/D patients. These results were however not confirmed by the histopathological study. Differently, Corrado et al.57 demonstrated that some patients with RVOT VT in the absence of RV dilatation and/or dysfunction showed electroanatomical scar in the RVOT corresponding to histopathological features diagnostic of early ARVC/D, like fibro-fatty myocardial replacement, conditioning malignant arrhythmic course. This was consistent with the current perspective on the ARVC/D natural history, and with an early “concealed” phase with subtle RV structural changes that can be identified by 3D-EAVM with a high degree of sensitivity of 100% and specificity of 95%. Santangeli et al.58 compared CMR with 3D-EAVM for scar identification in patients with RV arrhythmias and structural heart disease evidenced at EMB, confirming that 3D-EAVM is more sensitive than DE-CMR, particularly in cases of small scars, and should be used as mapping guide for EMB. Their conclusion was that 3D-EAVM with EMB should be considered when the clinical suspicion is high, because absence of DE does not reliably rule out abnormal myocardial substrates.58

Recently, Perazzolo Marra and co-workers confirmed that currently available DE-CMR visualizes RV scars unsatisfactorily: based on their findings, it seems that DE-CMR and 3D-EAVM should not be considered alternative imaging tools in ARVC/D patients, but they should be used synergistically to combine their strategic diagnostic and prognostic information regarding quantitative evaluation of RV function and assessment of arrhythmogenic myocardial substrate.59

A new technique to predict the presence and extension of epicardial involvement in patients with ARVC/D undergoing endocardial EAVM was proposed by the Marchlinski’s group. This technique shows that, in patients with limited endocardial substrate, endocardial unipolar intracardiac electrograms (EGMs) <5.5 mV well correlate with electrogram abnormalities detected from the epicardial aspect in patients with ARVC/D.60 therefore endocardial unipolar electrogram abnormalities may represent the clue of an early “epicardial” disease, that requires further investigation (figure 3).

Radiofrequency Catheter Ablation In IdioVAs And ARVC/D

RFCA of IdioVAs arising from the RVOT is based on two main methods of mapping: activation mapping and pace-mapping. In addition, both available 3D-EAVM systems, CARTOTM (Biosense-Webster, Diamond Bar, CA, USA) or NavXTM (St. Jude Medical, St. Paul, MN, USA), are widely used to relate the anatomy to the mapping data (figure 4, panel A). During activation mapping, the earliest intracardiac bipolar electrogram recorded from the mapping catheter is compared with the surface QRS onset, with an expected advance of 20 to 40 milliseconds (figure 4, panel B-C); a sharp “QS” deflection at the unipolar recording should confirm the site of origin of the arrhythmia. Of note, unipolar EGMs have been related to a high sensitivity for successful ablation sites, but may also be recorded at unsuccessful sites up to 11 mm from the site of origin.62-64 Pacemapping has been proposed to confirm the activation mapping findings and in particular if PVCs are not frequent or VT is not inducible. It should be performed using as little current as needed to reliably capture and at the same cycle length of VT or similar, and perfect match on a 12-lead ECG with regard to spontaneous arrhythmias is mandatory.65-67

Accordingly to the available published data in respect of the outcome of RFCA for IdioVAs, acute procedural success was reported in 93% of patients, with about 5% of recurrence risk.68
Serious complications were described in approximately 1% of patients, primarily related to myocardial perforation. For this reason, the integration with the new available technologies, such as contact force information, is mandatory to reduce the risk of perforation mostly due to the relatively thin structure of the RVOT.\textsuperscript{16}

RFCA of VAs in ARVC/D patients is not considered curative and thus is not a first-line therapy.\textsuperscript{13-15} The results of RFCA in the setting of ARVC/D-related VAs substantially vary among the several single-
These unsatisfactory results achieved with RFCA may be related to an inadequate characterization of the substrate. Considering the diffuse substrate of ARVC/D and the predominant epicardial involvement and taking into account the relevant incidence of failure using an endocardial-only approach, Garcia et al. described the role of a combined endo-epicardial substrate-based ablation approach to improve the outcomes in ARVC/D patient population. In this study the feasibility of endo-epicardial substrate-based approach to improve arrhythmia control was demonstrated, underlying importance of targeting the epicardium to further optimize long-term clinical outcome. During a mean follow-up of 18±12 months from RFCA, 77% of patients have no VT recurrence. Bai and coworkers interestingly suggested that the endo-epicardial approach not only increased long-term arrhythmia-free survival but was more likely to result in discontinuation of antiarrhythmic drugs. Berruezo et al. showed that a combined endo-epicardial mapping reveals larger epicardial substrate in patients with ARVC/D, confirming the low efficacy of the endocardial-only strategy. Moreover, it was demonstrated that using the endo-epicardial approach including scar dechannelling technique is possible to achieve a high acute success rate with low incidence of recurrence during follow-up.

RFCA results in a significant reduction in the VT burden among patients with ARVC/D, regardless of ablation strategy. However, despite the better results using the epicardial approach, recurrence rates remain considerable as shown by Philips et al. In their series of 87 ARVC/D patients undergoing RFCA, they reported a cumulative freedom from VT after epicardial ablation of 64% and 45% at 1 and 5 years, which was significantly longer than with the endocardial approach.

**Conclusion**

IdioVAs and ARVC/D, even at the early stage, are fundamentally different entities. Nevertheless, clinical presentation is not unequivocal, so that, particularly in early stage of ARVC/D, non-invasive diagnostic tools may direct towards one or the other suspected diagnosis. ECG differences in sinus rhythm between IdioVAs and early stage ARVC/D may be unremarkable, whilst, during VAs different ECG and intracardiac findings have been identified to assist in the differential diagnosis. Currently available imaging techniques are of fundamental importance to recognize RV structural and functional abnormalities and the combined information derived from CMR and 3D-EAVM represent the most effective tool for the identification of myocardial abnormalities in early stages of the disease. The role of RFCA is well established in the setting of IdioVAs, whilst more and more evidences support the use of a combined endo-epicardial substrate-based approach to effectively control the arrhythmic burden in ARVD patients, modifying the course of the disease in a prognostic way.

**References**

ventricular dysplasia and right ventricular outflow tract tachycardia. Eur Heart J 2003;24:801-810.


